Taysha Gene Therapies Announces Expanded Eligibility in REVEAL Phase 1/2 Adult Trial to Include Adolescent Rett Syndrome Patients
Health Canada authorized the Company’s protocol amendment that expands eligibility to include patients aged 12 and older with stage four Rett syndrome in the REVEAL Phase 1/2 adult trial in Canada
Related news for (TSHA)
- Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program
- 24/7 Market News Snapshot 29 May, 2025 – Taysha Gene Therapies, Inc. Common Stock (NASDAQ:TSHA)
- Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
- Taysha Gene Therapies Announces Pivotal Part B Trial Design Details for TSHA-102 in Rett Syndrome Enabled by IRSF Natural History Data and Positive Clinical Data from Part A of the REVEAL Adult/Adolescent and Pediatric Trials Evaluating TSHA-102
- Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants